Pfizer strikes $2.63 billion CAR-T deal with Starna Therapeutics to target autoimmune diseases

By: IPP Bureau

Last updated : November 19, 2026 9:49 am



Pfizer will pay Starna $330 million upfront, with the latter eligible for up to $2.3 billion in additional milestone payments tied to development and commercial achievements


Pfizer has struck a major licensing deal worth up to $2.63 billion with biotechnology company Starna Therapeutics to develop next-generation CAR-T therapies targeting autoimmune diseases, strengthening its presence in the rapidly evolving field of cell therapy.
 
Under the exclusive licensing agreement, Pfizer will pay Starna $330 million upfront, with the latter eligible for up to $2.3 billion in additional milestone payments tied to development and commercial achievements, along with royalties on net sales of approved products.
 
The agreement gives Pfizer exclusive rights outside Greater China to develop, manufacture and commercialise three pre-investigational new drug (pre-IND) in vivo chimeric antigen receptor T-cell (CAR-T) programmes focused on autoimmune diseases.
 
The deal also grants Pfizer rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, as well as oncology. Pfizer will additionally have options to exclusively license compounds emerging from a separate research collaboration and expand its territorial rights to Greater China.
 
The partnership marks a significant move by Pfizer to explore the potential of in vivo CAR-T technology, an emerging approach that could open new treatment avenues for patients with autoimmune conditions who do not respond adequately to existing therapies.
 
“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches," said Michael Vincent, Chief Inflammation & Immunology Officer, Pfizer.
 
For Starna, the agreement provides access to Pfizer’s global development and manufacturing capabilities to advance its RNA-based therapeutic platform.
 
“Our vision at Starna is to unlock the potential of RNA medicines to transform patient care. We believe our proprietary targeted LNP delivery platform and RNA technology provide a strong foundation for advancing in vivo CAR-T therapies. We are excited to join forces with Pfizer, a global leader in drug development, to bring transformative therapies to patients worldwide," said Rongkuan Hu, Chief Executive Officer, Starna Therapeutics.
 
Under the terms of the agreement, Pfizer will lead clinical development outside Greater China and manufacture the finished drug product for the initial clinical trials at its facilities in the United States. The pharmaceutical giant will retain sole and exclusive commercialisation rights for all products in territories covered by the agreement.
 
The deal expands Pfizer’s inflammation and immunology pipeline and brings Starna’s proprietary RNA delivery technology into its broader research and development strategy.
 
In vivo CAR-T is attracting growing interest as a potential alternative to conventional CAR-T approaches. Rather than engineering a patient's T cells outside the body and reinfusing them, the approach aims to modify immune cells directly inside the body. The technology could potentially simplify treatment delivery and expand access to cell therapies, although its clinical potential remains to be established.
 
For Pfizer, the collaboration represents an opportunity to combine its expertise in RNA-based medicines, immunology research, clinical development and global commercialisation with Starna’s targeted lipid nanoparticle (LNP) delivery platform.
 
The success of the programmes, however, will depend on their progression through preclinical research, clinical trials and regulatory evaluation. All three licensed CAR-T programmes remain at the pre-IND stage.

Pfizer Starna Therapeutics autoimmune diseases

First Published : November 19, 2026 12:00 am